LumiraDx Limited Warrant
LMDXW
LMDXW was delisted on the 8th of January, 2024.
21 hedge funds and large institutions have $17.7M invested in LumiraDx Limited Warrant in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 20 → 21 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
52% less capital invested
Capital invested by funds: $37.1M → $17.7M (-$19.4M)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$113K |
| 2 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$23.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVS Health
Woonsocket,
Rhode Island
|
-$155K |
| 2 |
Walleye Capital
New York
|
-$45.7K |
| 3 |
AGM
Alpine Global Management
New York
|
-$13.6K |
| 4 |
HF
HRT Financial
New York
|
-$2.58K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$346 |
LMDXW Hedge Fund Activity: Q2 2022 in Review
21 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in LumiraDx Limited Warrant (LMDXW) for Q2 2022, worth a combined $17.7M — down 52% from $37.1M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LMDXW positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 5 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $113K. The largest seller was CVS Health, cutting an estimated $155K.
- 21 institutional investors held LumiraDx Limited Warrant (LMDXW) as of Q2 2022, up from 20 in Q1 2022.
- Funds reported $17.7M of LumiraDx Limited Warrant stock for Q2 2022, down 52% quarter-over-quarter.
- 3 funds opened new LumiraDx Limited Warrant positions in Q2 2022 and 2 closed out, a net change of +1 holder.
- The largest LumiraDx Limited Warrant buyer in Q2 2022 was Balyasny Asset Management, an estimated $113K added.
- The largest LumiraDx Limited Warrant seller in Q2 2022 was CVS Health, an estimated $155K sold.
Based on aggregated 13F filings for Q2 2022.